Austrianni is a start-up biotechnology company focused on developing novel biological therapies for the treatment of infectious diseases that are of major global significance.

The company has a primary emphasis on therapies for tuberculosis. Austrianni’s strengths lie in its immunological, genetic, and microbiological expertise, and in its access to state-of-the-art technology for monoclonal antibody discovery.